11 articles
How checkpoint inhibitors unleash the immune system to fight cancer.
How genomic testing works, when it is recommended, and how to understand results.
How PARP inhibitors exploit BRCA deficiency to selectively kill cancer cells.
Combination BRAF and MEK inhibitors have improved survival in BRAF-mutant melanoma.
KRAS was once considered undruggable; now targeted inhibitors are approved.
HER2-targeted therapies that have transformed outcomes in HER2-positive breast cancer.
How ALK rearrangements are detected and treated with ALK inhibitors.
Understanding EGFR alterations and approved targeted therapies for lung cancer.
An overview of biomarkers such as EGFR, ALK, HER2, KRAS, and BRAF.
